Trials / Completed
CompletedNCT03585517
Safety and Efficacy Evaluation of IM23 CAR-T Cells (IM23CAR-T)
Safety and Efficacy Evaluation of IM23 CAR-T Cells On CD123+ AML Patients
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 10 (actual)
- Sponsor
- Beijing Immunochina Medical Science & Technology Co., Ltd. · Industry
- Sex
- All
- Age
- 3 Years – 80 Years
- Healthy volunteers
- Not accepted
Summary
Assessment of the Safety and Feasibility of Administering T Cells Expressing an Anti-CD123 Chimeric Antigen Receptor to Patients With CD123+ AML
Detailed description
Assessment of the Safety and Feasibility of Administering T Cells Expressing an Anti-CD123 Chimeric Antigen Receptor to Patients With CD123+ AML and determine the best dosage.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | IM23 | T Cells Expressing an Anti-CD123 Chimeric Antigen Receptor |
Timeline
- Start date
- 2018-07-21
- Primary completion
- 2020-08-01
- Completion
- 2020-10-01
- First posted
- 2018-07-13
- Last updated
- 2023-01-19
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT03585517. Inclusion in this directory is not an endorsement.